Related references
Note: Only part of the references are listed.Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer
Dionysios Papadatos-Pastos et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
Pancreatic Adenocarcinoma
David P. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design
Matthew H. G. Katz et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
A. H. Ko et al.
BRITISH JOURNAL OF CANCER (2013)
Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study
R. P. Jones et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Human Carboxylesterase-2 Hydrolyzes the Prodrug of Gemcitabine (LY2334737) and Confers Prodrug Sensitivity to Cancer Cells
Susan E. Pratt et al.
CLINICAL CANCER RESEARCH (2013)
Clinical implications of CES2 RNA expression in neuroblastoma
Keiichi Uchida et al.
JOURNAL OF PEDIATRIC SURGERY (2013)
Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy
Ching-Wei D. Tzeng et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
Matthew H. G. Katz et al.
CANCER (2012)
The pharmacological landscape and therapeutic potential of serine hydrolases
Daniel A. Bachovchin et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Detection and Quantification of Carboxylesterase 2 Activity by Capillary Electrophoresis
Joana Lamego et al.
ANALYTICAL CHEMISTRY (2011)
Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11
M. Jason Hatfield et al.
BIOCHEMICAL PHARMACOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Monoacylglycerol Lipase Regulates a Fatty Acid Network that Promotes Cancer Pathogenesis
Daniel K. Nomura et al.
CELL (2010)
Activity-based Proteomics of Enzyme Superfamilies: Serine Hydrolases as a Case Study
Gabriel M. Simon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
RBBP9: A tumor-associated serine hydrolase activity required for pancreatic neoplasia
David J. Shields et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice
Michael P. Kim et al.
NATURE PROTOCOLS (2009)
Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer
Rosa F. Hwang et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma
Hiroki Yano et al.
CANCER SCIENCE (2008)
Expression and characterization of a human carboxylesterase 2 splice variant
Marissa A. Schiel et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Hydrolysis of pyrethroids by human and rat tissues: Examination of intestinal, liver and serum carboxylesterases
J. Allen Crow et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2007)
A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer
Hideki Ueno et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway
Woonyoung Choi et al.
CANCER BIOLOGY & THERAPY (2006)
Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma
B Li et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide
SK Quinney et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo
N Jessani et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Characteristic expression profiles induced by genotoxic carcinogens in rat liver
H Ellinger-Ziegelbauer et al.
TOXICOLOGICAL SCIENCES (2004)
The emerging roles of human tissue kallikreins in cancer
CA Borgoño et al.
NATURE REVIEWS CANCER (2004)
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity
Y Xu et al.
ANNALS OF ONCOLOGY (2002)
Multiple pathways of cell invasion are regulated by multiple families of serine proteases
M Del Rosso et al.
CLINICAL & EXPERIMENTAL METASTASIS (2002)
Irinotecan in the treatment of colorectal cancer: Clinical overview
U Vanhoefer et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)